IE46005B1 - Preparations of 3-n-pyrrolidino-4-phenoxy-5-sulfamyl-benzoic acid and process for their manufacture - Google Patents
Preparations of 3-n-pyrrolidino-4-phenoxy-5-sulfamyl-benzoic acid and process for their manufactureInfo
- Publication number
- IE46005B1 IE46005B1 IE2474/77A IE247477A IE46005B1 IE 46005 B1 IE46005 B1 IE 46005B1 IE 2474/77 A IE2474/77 A IE 2474/77A IE 247477 A IE247477 A IE 247477A IE 46005 B1 IE46005 B1 IE 46005B1
- Authority
- IE
- Ireland
- Prior art keywords
- particles
- active substance
- pharmaceutical preparation
- coating
- coated
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 17
- 238000002360 preparation method Methods 0.000 title claims description 10
- 238000004519 manufacturing process Methods 0.000 title claims 2
- 239000002253 acid Substances 0.000 claims abstract description 10
- 239000013543 active substance Substances 0.000 claims description 35
- 239000000203 mixture Substances 0.000 claims description 21
- 239000002245 particle Substances 0.000 claims description 21
- 239000011248 coating agent Substances 0.000 claims description 20
- 238000000576 coating method Methods 0.000 claims description 20
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 17
- 239000008188 pellet Substances 0.000 claims description 15
- 238000000338 in vitro Methods 0.000 claims description 11
- 239000000463 material Substances 0.000 claims description 9
- 229920001800 Shellac Polymers 0.000 claims description 8
- 235000021355 Stearic acid Nutrition 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 8
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 8
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 8
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 claims description 8
- 239000004208 shellac Substances 0.000 claims description 8
- 229940113147 shellac Drugs 0.000 claims description 8
- 235000013874 shellac Nutrition 0.000 claims description 8
- 239000008117 stearic acid Substances 0.000 claims description 8
- 239000000853 adhesive Substances 0.000 claims description 7
- 230000001070 adhesive effect Effects 0.000 claims description 7
- 230000007935 neutral effect Effects 0.000 claims description 7
- 239000000243 solution Substances 0.000 claims description 7
- 239000000454 talc Substances 0.000 claims description 7
- 229910052623 talc Inorganic materials 0.000 claims description 7
- 239000011230 binding agent Substances 0.000 claims description 6
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 5
- 239000004925 Acrylic resin Substances 0.000 claims description 4
- 229920000178 Acrylic resin Polymers 0.000 claims description 4
- 239000007853 buffer solution Substances 0.000 claims description 4
- 239000001913 cellulose Substances 0.000 claims description 4
- 229920002678 cellulose Polymers 0.000 claims description 4
- 239000000945 filler Substances 0.000 claims description 4
- 230000001476 alcoholic effect Effects 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims 3
- 229920002845 Poly(methacrylic acid) Polymers 0.000 claims 2
- -1 N - pyrrolidino - 4 - phenoxy - 5 - sulphamyl benzoic acid Chemical compound 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 abstract 1
- UJEWTUDSLQGTOA-UHFFFAOYSA-N Piretanide Chemical compound C=1C=CC=CC=1OC=1C(S(=O)(=O)N)=CC(C(O)=O)=CC=1N1CCCC1 UJEWTUDSLQGTOA-UHFFFAOYSA-N 0.000 description 19
- 229960001085 piretanide Drugs 0.000 description 18
- 230000000979 retarding effect Effects 0.000 description 12
- 208000004880 Polyuria Diseases 0.000 description 6
- 230000035619 diuresis Effects 0.000 description 6
- 206010020852 Hypertonia Diseases 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical class CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 2
- 229940024546 aluminum hydroxide gel Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000007888 film coating Substances 0.000 description 2
- 238000009501 film coating Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011866 long-term treatment Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229920001059 synthetic polymer Polymers 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229940083181 centrally acting adntiadrenergic agent methyldopa Drugs 0.000 description 1
- 239000007931 coated granule Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 238000010410 dusting Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 238000005243 fluidization Methods 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 1
- 229960003147 reserpine Drugs 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
- 230000000894 saliuretic effect Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19762655331 DE2655331A1 (de) | 1976-12-07 | 1976-12-07 | Zubereitungsformen von 3-n-pyrrolidino-4-phenoxy-5-sulfamyl-benzoesaeure und verfahren zu ihrer herstellung |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IE46005L IE46005L (en) | 1978-06-07 |
| IE46005B1 true IE46005B1 (en) | 1983-01-26 |
Family
ID=5994862
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IE2474/77A IE46005B1 (en) | 1976-12-07 | 1977-12-06 | Preparations of 3-n-pyrrolidino-4-phenoxy-5-sulfamyl-benzoic acid and process for their manufacture |
Country Status (15)
| Country | Link |
|---|---|
| JP (1) | JPS5372815A (da) |
| AT (1) | AT355216B (da) |
| AU (1) | AU513409B2 (da) |
| BE (1) | BE861608A (da) |
| DE (1) | DE2655331A1 (da) |
| DK (1) | DK542877A (da) |
| ES (1) | ES464642A1 (da) |
| FR (1) | FR2373280A1 (da) |
| GB (1) | GB1569018A (da) |
| IE (1) | IE46005B1 (da) |
| IL (1) | IL53539A0 (da) |
| NL (1) | NL7713392A (da) |
| NZ (1) | NZ185855A (da) |
| PT (1) | PT67370B (da) |
| ZA (1) | ZA777204B (da) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2025085B3 (es) * | 1986-04-29 | 1992-03-16 | Hoechst-Roussel Pharmaceuticals Incorporated | Una estructura laminar para la administracion de un producto quimico a una velocidad de liberacion controlada. |
| SE460947B (sv) * | 1986-08-26 | 1989-12-11 | Lejus Medical Ab | En multiple-unit-dos komposition av l-dopa |
| CN1072215C (zh) * | 1995-02-22 | 2001-10-03 | 赫彻斯特药品和化学品公司 | 无定形吡咯他尼、吡咯他尼多晶型物,其制备方法和用途 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE33874B1 (en) * | 1968-12-24 | 1974-11-27 | Leo Pharm Prod Ltd | New sulphamyl-benzoic acid derivatives |
-
1976
- 1976-12-07 DE DE19762655331 patent/DE2655331A1/de active Pending
-
1977
- 1977-12-01 ES ES464642A patent/ES464642A1/es not_active Expired
- 1977-12-02 NL NL7713392A patent/NL7713392A/xx not_active Application Discontinuation
- 1977-12-05 NZ NZ185855A patent/NZ185855A/xx unknown
- 1977-12-05 IL IL53539A patent/IL53539A0/xx unknown
- 1977-12-05 ZA ZA00777204A patent/ZA777204B/xx unknown
- 1977-12-06 PT PT67370A patent/PT67370B/pt unknown
- 1977-12-06 DK DK542877A patent/DK542877A/da not_active Application Discontinuation
- 1977-12-06 IE IE2474/77A patent/IE46005B1/en unknown
- 1977-12-06 AT AT873777A patent/AT355216B/de not_active IP Right Cessation
- 1977-12-06 AU AU31274/77A patent/AU513409B2/en not_active Expired
- 1977-12-07 BE BE183258A patent/BE861608A/xx unknown
- 1977-12-07 GB GB50915/77A patent/GB1569018A/en not_active Expired
- 1977-12-07 JP JP14619077A patent/JPS5372815A/ja active Pending
- 1977-12-07 FR FR7736876A patent/FR2373280A1/fr active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| AU513409B2 (en) | 1980-11-27 |
| FR2373280A1 (fr) | 1978-07-07 |
| NZ185855A (en) | 1979-10-25 |
| JPS5372815A (en) | 1978-06-28 |
| DK542877A (da) | 1978-06-08 |
| PT67370A (de) | 1978-01-01 |
| ES464642A1 (es) | 1978-09-01 |
| ATA873777A (de) | 1979-07-15 |
| AT355216B (de) | 1980-02-25 |
| GB1569018A (en) | 1980-06-11 |
| PT67370B (de) | 1979-09-20 |
| AU3127477A (en) | 1979-06-14 |
| IL53539A0 (en) | 1978-03-10 |
| NL7713392A (nl) | 1978-06-09 |
| BE861608A (fr) | 1978-06-07 |
| IE46005L (en) | 1978-06-07 |
| FR2373280B1 (da) | 1980-06-20 |
| ZA777204B (en) | 1978-10-25 |
| DE2655331A1 (de) | 1978-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US3773920A (en) | Sustained release medicinal composition | |
| US5370880A (en) | Pharmaceutical formulations containing acrivastine | |
| AU709887B2 (en) | Long-lasting release Nifedipine preparation | |
| CA2281420C (en) | Preparation of pharmaceutically-active granules | |
| JP2535339B2 (ja) | 活性物質の制御速度制御用装置 | |
| US4533540A (en) | Nitroglycerin-containing polymeric matrix for sustained release on topical application | |
| US3074852A (en) | Pharmaceuticals with delayed release | |
| CA2265766C (en) | Rapidly disintegrating pellets | |
| DE2336218C3 (de) | Orale Arzneiform | |
| US5275825A (en) | Compressed-molded preparations | |
| US4806361A (en) | Medicaments in sustained release unit dose form | |
| AU592731B2 (en) | Nitrofurantoin dosage form | |
| JPS6323814A (ja) | 経口投与形体の徐放性医薬組成物 | |
| JPH0643312B2 (ja) | 薬学的調合剤 | |
| JPH06503311A (ja) | 薬理学的に活性なイオン化可能物質を含有する新規な医薬製剤およびその製造法 | |
| IL102777A (en) | Pharmaceutical combination formulation | |
| CA1261268A (en) | Theophylline sustained release formulation | |
| GB1593062A (en) | Coatings | |
| CA1184497A (en) | Pharmaceutical composition | |
| JPH0764725B2 (ja) | 徐放性錠剤およびその製造方法 | |
| US5230901A (en) | Sustained release tablet of a mixture of alginates and polyacrylates | |
| GB1569018A (en) | Preparations of 3-n-pyrrolidino-4-phenoxy-5-sulphamyl-benzolc acid and process for their manufacture | |
| US5968552A (en) | Diltiazem hydrochloride formulation | |
| JPH01313431A (ja) | ジルチアゼム・マイクロビーズ、その製法および徐放性医薬組成物 | |
| CN102970980A (zh) | 控制释放的左乙拉西坦配方 |